World Health Organization Sounds Concern Over Critical Scarcity of Obesity Medications
Less than one in 10 patients that would benefit from GLP-1 drugs such as Wegovy have access to them, warns the global health agency as it publishes its initial recommendations on the drugs.
Given in excess of 1,000,000,000 people worldwide now living with obesity, it is urging increased and just access to these injectable treatments.
Per forecasts, more than two billion could be obese by 2030 if no action is taken.
"The new guidelines acknowledges that excess weight is a long-term condition that can be treated with thorough and lifelong care," said WHO director-general Tedros Adhanom Ghebreyesus.
High costs, limited production capacity, and distribution challenges are significant barriers to widespread availability to the treatments that can help people shift substantial body mass, explains the organization.
Weight-Loss Drug Supply Crisis
Despite the current most optimistic case, the manufacturing of such drugs could only cover about 100 million people – under 10% of eligible patients, per the health organization.
The guideline encourages governments and firms to expand availability, via strategies including patent sharing.
The intellectual property rights on a key compound – the core component of the drug Wegovy – is scheduled to end in several countries in 2026.
How Obesity Jabs Operate
The injections imitate a biological compound to reduce digestion speed, suppress the appetite and boost feelings of fullness so users consume fewer calories.
People commonly start to lose weight after several weeks of beginning the regular doses.
Evidence indicates patients may see weight return after a year of stopping the medication, when their typical appetite resume.
Being carrying excess weight elevates your likelihood for contracting medical conditions, such as diabetes, heart disease, brain attack, and some cancers.
Obesity concerns people in all nations and was associated with millions of fatalities worldwide in 2024, per the WHO.
